全文获取类型
收费全文 | 695篇 |
免费 | 29篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 42篇 |
妇产科学 | 13篇 |
基础医学 | 57篇 |
口腔科学 | 37篇 |
临床医学 | 61篇 |
内科学 | 208篇 |
皮肤病学 | 14篇 |
神经病学 | 14篇 |
特种医学 | 154篇 |
外科学 | 48篇 |
综合类 | 13篇 |
预防医学 | 19篇 |
眼科学 | 6篇 |
药学 | 22篇 |
中国医学 | 1篇 |
肿瘤学 | 19篇 |
出版年
2023年 | 4篇 |
2021年 | 8篇 |
2020年 | 5篇 |
2019年 | 5篇 |
2018年 | 11篇 |
2017年 | 5篇 |
2016年 | 3篇 |
2015年 | 11篇 |
2014年 | 18篇 |
2013年 | 20篇 |
2012年 | 11篇 |
2011年 | 9篇 |
2010年 | 29篇 |
2009年 | 40篇 |
2008年 | 29篇 |
2007年 | 24篇 |
2006年 | 11篇 |
2005年 | 16篇 |
2004年 | 14篇 |
2003年 | 14篇 |
2002年 | 3篇 |
2001年 | 8篇 |
2000年 | 12篇 |
1999年 | 23篇 |
1998年 | 29篇 |
1997年 | 38篇 |
1996年 | 45篇 |
1995年 | 29篇 |
1994年 | 25篇 |
1993年 | 35篇 |
1992年 | 8篇 |
1991年 | 6篇 |
1990年 | 22篇 |
1989年 | 13篇 |
1988年 | 14篇 |
1987年 | 18篇 |
1986年 | 25篇 |
1985年 | 10篇 |
1984年 | 9篇 |
1983年 | 7篇 |
1982年 | 19篇 |
1981年 | 9篇 |
1980年 | 6篇 |
1979年 | 2篇 |
1977年 | 9篇 |
1976年 | 7篇 |
1975年 | 7篇 |
1971年 | 1篇 |
1967年 | 1篇 |
1934年 | 1篇 |
排序方式: 共有730条查询结果,搜索用时 0 毫秒
1.
D Gröne† R Treudler† EM de Villiers‡ R Husak† CE Orfanos† ChC Zouboulis†§ 《Journal of the European Academy of Dermatology and Venereology》2006,20(2):202-205
Cidofovir is an acyclic nucleoside phosphonate with broad-spectrum activity against DNA viruses, including human papilloma virus (HPV). However, data on the efficacy of cidofovir in an immunosuppressive setting remain contradictory. We report for the first time on the promotion of the healing of recalcitrant warts in a patient with myelodysplastic syndrome with intravenous cidofovir treatment. 相似文献
2.
3.
Picotamide inhibition of excess in vitro thromboxane B2 release by colorectal mucosa in inflammatory bowel disease. 总被引:1,自引:0,他引:1
Collins CE Benson MJ Burnham WR Rampton DS 《Alimentary pharmacology & therapeutics》1996,10(3):315-320
BACKGROUND: Inflammatory bowel disease is associated with increased mucosal release of eicosanoids. Among these, thromboxane A2 has been proposed as a possible inflammatory mediator; its suppression may be a useful therapeutic option. METHODS: Using a tissue incubation technique, we compared release of immunoreactive thromboxane B2 by colonic biopsies from patients with ulcerative colitis, Crohn's disease and controls, and assessed the inhibitory effect of picotamide, a thromboxane synthesis inhibitor-receptor antagonist, which has been widely used in Italy for management of ischaemic heart and cerebrovascular disease. RESULTS: Increased amounts of thromboxane B2 were released from biopsies from patients with active ulcerative colitis (median 238 pg/20 min/mg wet weight (interquartile range 147- 325), n = 12) and active Crohn's disease (252 (174-450), 6) compared with those from patients with quiescent ulcerative colitis (95 (61- 140), 12) or Crohn's disease (105 (57-201), 13), or controls (136 (64- 206), 8). Incubation with picotamide at concentrations between 100 microM and 1 mM reduced thromboxane B2 release (IC50 890 microM). CONCLUSION: Since increased thromboxane A2 production may have pathogenetic importance, thromboxane synthesis inhibitor-receptor antagonists such as picotamide merit therapeutic trial in the management of inflammatory bowel disease. 相似文献
4.
5.
Higher fat and energy intakes confer a survival advantage in cystic fibrosis (CF). There is a need to develop effective nutrition programmes that ensure optimal energy intake in CF.
A cross-sectional measurement of clinical characteristics and energy and fat intakes in patients attending the CF outpatients clinic of the John Hunter Hospital, Newcastle was undertaken. Twenty-nine subjects, mean age 12 years (range 4.3–20.2), completed weighed food records to determine the contribution of fat to the percentage of the recommended energy intake obtained and to document use of pancreatic enzyme replacement therapy.
Diets with a high percentage of energy derived from fat did not guarantee that individuals with CF met their energy requirements. Subjects with total fat intakes of 100 g per day or greater, however, achieved in excess of 110% recommended daily intake (RDI) for energy. Up to 47% of subjects consumed more pancreatic enzyme replacement capsules than shown to give maximum effectiveness.
Setting a 100 g daily fat target is a realistic way of ensuring high energy intakes in CF. Fat ready reckoners would identify the fat content of food and prescribe specific numbers of pancreatic enzyme replacement capsules to be consumed with each meal or food item. 相似文献
Methodology:
A cross-sectional measurement of clinical characteristics and energy and fat intakes in patients attending the CF outpatients clinic of the John Hunter Hospital, Newcastle was undertaken. Twenty-nine subjects, mean age 12 years (range 4.3–20.2), completed weighed food records to determine the contribution of fat to the percentage of the recommended energy intake obtained and to document use of pancreatic enzyme replacement therapy.
Results:
Diets with a high percentage of energy derived from fat did not guarantee that individuals with CF met their energy requirements. Subjects with total fat intakes of 100 g per day or greater, however, achieved in excess of 110% recommended daily intake (RDI) for energy. Up to 47% of subjects consumed more pancreatic enzyme replacement capsules than shown to give maximum effectiveness.
Conclusion:
Setting a 100 g daily fat target is a realistic way of ensuring high energy intakes in CF. Fat ready reckoners would identify the fat content of food and prescribe specific numbers of pancreatic enzyme replacement capsules to be consumed with each meal or food item. 相似文献
6.
Heart failure (HF) is highly prevalent and associated with adverse outcomes and high costs. Compared with the general population, depression is up to five times more common in HF patients. Comorbid depression increases morbidity and mortality risk and health-care expenditures even further and decreases quality of life. Possible, often interrelated, mediators of these effects include biological, behavioral, and psychosocial factors. Screening instruments such as the self-administered PHQ-2 facilitate detection of patients at risk. Although antidepressants may improve psychological well-being, no positive effects on hard clinical endpoints have been demonstrated to date. 相似文献
7.
CE Faggons C Mabedi CG Shores S Gopal 《Malawi medical journal : the journal of Medical Association of Malawi》2015,27(3):79-87
Aim
Review the literature from 1990 to 2013 to determine known anatomic sites, risk factors, treatments, and outcomes of head and neck squamous cell carcinoma (HNSCC) in sub-Saharan Africa.Methods
Using a systematic search strategy, literature pertaining to HNSCC in sub-Saharan Africa was reviewed and patient demographics, anatomic sites, histology, stage, treatment, and outcomes were abstracted. The contributions of human immunodeficiency virus (HIV), human papillomavirus (HPV) and behavioural risk factors to HNSCC in the region were assessed.Results
Of the 342 papers identified, 46 were utilized for review, including 8611 patients. In sub-Saharan Africa, the oropharyngeal/oral cavity was found to be the most common site, with 7750 cases (90% of all cases). Few papers distinguished oropharyngeal from oral cavity, making identification of possible HPV-associated oropharyngeal squamous cell carcinoma (SCC) difficult. SCC of the nasopharynx, nasal cavity, or paranasal sinuses was identified in 410 patients (4.8% of all cases). Laryngeal SCC was found in 385 patients (4.5% of all cases), and only 66 patients (0.8% of all cases) with hypopharyngeal SCC were identified. In 862 patients with data available, 43% used tobacco and 42% used alcohol, and reported use varied widely and was more common in laryngeal SCC than that of the oropharyngeal/oral cavity. Toombak and kola nut use was reported to be higher in patients with HNSCC. Several papers reported HIV-positive patients with HNSCC, but it was not possible to determine HNSCC prevalence in HIV-positive compared to negative patients. Reports of treatment and outcomes were rare.Conclusions
The oropharyngeal/oral cavity was by far the most commonly reported site of HNSCC reported in sub-Saharan Africa. The roles of risk factors in HNSCC incidence in sub-Saharan Africa were difficult to delineate from the available studies, but a majority of patients did not use tobacco and alcohol. 相似文献8.
Norbert Moszner Urs Karl Fischer J?rg Angermann Volker Rheinberger 《Dental materials》2008,24(5):694-699
OBJECTIVES: The objective of this study was to investigate the use of a new, partially aromatic urethane dimethacrylate in visible-light cured resin-based composite restoratives. Selected mechanical properties, such as flexural strength and flexural modulus of elasticity, of model monomer mixtures and composites containing the new urethane dimethacrylate were investigated and compared to the properties of materials that are based on Bis-GMA, at present the most frequently used cross-linker in restorative composites. In addition, the polymerization shrinkage and the water sorption of selected composites were determined. METHODS: The flexural strength, flexural modulus of elasticity, and the water sorption were determined according to ISO 4049:2000. Test specimens (rods: 2 mmx2 mmx25 mm; discs: d=15 mm and h=1 mm) of the investigated composites were prepared in stainless steel molds and light-cured (150 mW/cm2, 2x180 s). The flexural strength and flexural modulus of rods were measured after the samples had been stored under dry conditions or in water for 24 h at 37 degrees C as well as after they had been stored in water for 7 days at 37 degrees C. The water sorption was determined with discs. The polymerization shrinkage was calculated from the densities of the uncured composite pastes and cured composites. RESULTS: Visible light cured mixtures of dimethacrylate diluents with the new urethane dimethacrylate and composites based on these mixtures show a reactivity, flexural strength, flexural modulus of elasticity, polymerization shrinkage and water sorption similar to those of materials that are based on Bis-GMA. The composites did not show any strong deterioration of the mechanical properties after water storage. 相似文献
9.
10.
Airway eosinophilia and expression of interleukin-5 protein in asthma and in exacerbations of chronic bronchitis 总被引:6,自引:0,他引:6
M. SAETTA A. DI STEFANO P. MAESTRELLI G. TURATO CE. MAPP M. PIENO G. ZANGUOCHI G. DEL PRETE† L. M. FABBRI 《Clinical and experimental allergy》1996,26(7):766-774
Background An increased nutnber of eosinophils in the bronchial mucosa has been demonstrated both in asthma and in exacerbations of chronic bronchitis. Oiyective To investigate whether the airway eosinophilia present in asthma and in chronic bronchitis during exacerbations is associated with interleukin (IL)-5 protein expression in the bronchial mucosa. Methods We obtained bronchial biopsies in 18 subjects with asthma (four intrinsic, seven extrinsic and seven occupational) and in II subjects with chronic bronchitis examined during an exacerbation. The findings were compared wilh those of bronchial biopsies from 10 subjects with chronic bronchitis examined under baseline conditions and from seven normal subjects, taken as controls. By immunohistochemistry, we assessed the expression of IL-5 protein and the number of eosinophils (EG2), mast cells ftryptase), and T-lymphocytes (CD3) in the submucosa. Results As compared with controls, the number of eosinophils was increased to a similar degree in both asthma (P < 0.001) and in exacerbations of ehronic bronchitis (P < 0.001). whereas the number of I L-5 immunopositive cells was increased significantly only in asthma (P < 0.01). No diflerences were observed in the number of tnast cells and T-lymphocytes between the four groups of subjects examined. Conciusions This study shows that the degree of airway eosinophilia is similar in asthma and in exacerbations of ehronic bronchitis, but only in asthma is it associated with an increased expression of I L-5 protein in the bronchial tnucosa. 相似文献